Business Today: Latest Business News, India economy News, Stock Markets, Sensex, Mutual Funds and Indian Tax
Loading...
Search

Total 220 results found. Search for [ Mylan ]

Results 1 to 21 of 220
PTI
March 2, 2021
The company has launched a generic product in the market after having received approval from the US and Drug Administration (U.S.FDA) earlier.


BusinessToday.In
October 16, 2020
The WHO said that the Solidarity trial looked at the effects of these treatments on overall mortality, initiation of ventilation, and duration of hospital stay in hospitalised patients


BusinessToday.In
September 1, 2020
Following the announcement, Biocon shares opened at Rs 382.05 and jumped 6.97% to its intraday high of Rs 402.65 against the last closing of Rs 376.40 on BSE. The stock trades near its 52-week high of Rs 455, hit on July 13, 2020


BusinessToday.In
September 1, 2020
Stocks to watch today on September 1: Biocon, Morepen Labs, Edelweiss, L&T, Bharat Dynamics among others are the top stocks to watch out for in Tuesday's trading session.


PB Jayakumar
August 13, 2020
Remdesivir price: Zydus is the fifth Indian company to launch the drug for coronavirus treatment after Hetero Labs, Cipla, Mylan NV and Jubilant Life Sciences. Priced at Rs 2,800 for a 100 mg lyophilized injection, its brand 'Remdac' will be the most economical


Reuters
August 13, 2020
Zydus has priced it at 2,800 rupees ($37.44) per 100mg vial. It will be sold under the brand name Remdac to government and private hospitals treating COVID-19 patients


BusinessToday.In
July 20, 2020
Remdesivir is one of the few medicines believed to be effective in treating coronavirus patients. So far, it has secured approvals for emergency use from US FDA and conditional approval from the European Commission.


BusinessToday.In
July 13, 2020
Last month, Cipla introduced Remdesivir under the brand name 'CIPREMI' after receiving approval from DCGI for \"restricted emergency use\" on adult and paediatric patients hospitalised with suspected or laboratory-confirmed COVID-19 infection


Reuters
July 9, 2020
Coronavirus update: The first batch of 10,000 vials had been printed with a price of 4,000 rupees, 800 rupees below the cheapest option, launched by European competitor Mylan this week


PB Jayakumar
July 8, 2020
Various medical shops have been telling buyers that the medicine is in short supply but can be made available If they are ready to pay a premium, DCGI has been informed


Joe C Mathew
July 7, 2020
DGCI has asked all state drug controllers to instruct their field officials to keep strict vigil to prevent black marketing and unauthorised sale of remdesivir


BusinessToday.In
New Delhi, July 6, 2020
DRDO has built a new temporary hospital with 1000 beds, including 250 ICU beds, in Delhi. The facility was constructed in just 11 days near the Indira Gandhi International (IGI) airport, on a piece of land belonging to the Ministry of Defence, for the treatment of coronavirus patients. The construction is a collaborative effort of DRDO and Tata Sons. Watch the video for more.Also Read: Coronavirus treatment: Mylan to offer remdesivir in India at Rs 4,800


BusinessToday.In
July 6, 2020
Mylan has been licensed by Gilead for marketing the drug in 127 low- and middle-income countries, including India. The company will manufacture remdesivir at its injectables facilities in India


BusinessToday.In
New Delhi, June 26, 2020
Coronavirus drug updates: The next batch of Hetero's Remdesivir will be sent to Kolkata, Lucknow, Patna, Indore, Bhopal, Bhubaneshwar, Ranchi, Kochi, Trivandrum, Vijayawada and Goa


BusinessToday.In
New Delhi, June 21, 2020
These two companies have been approved at a time when coronavirus cases in India are spiralling like never before and putting tremendous pressure on our healthcare system


BusinessToday.In
New Delhi, June 14, 2020
Remdesivir can be administered to patients with moderate disease (those on oxygen), though it should not administered to patients with severe renal impairment, pregnancy or lactating females and children, health ministry guidelines suggest


Associated Press
June 13, 2020
Four companies -- Hetero, Jubilant Life Sciences, Cipla and Mylan NV -- with which the original drug maker, Gilead Sciences Inc, have entered into non-exclusive licensing agreements are still awaiting nod from the DCGI for manufacturing and selling of remdesivir in India


BusinessToday.In
June 5, 2020
Stock Market LIVE Updates: Companies set to announce their earnings are State Bank of India, L&T, Jyothi Labs, Exide Industries, Saregama, Alkem Laboratories, Greaves Cotton, Gujarat Gas among others.


BusinessToday.In
June 5, 2020
Stocks to watch today on June 5: SBI, Exide, Bharti Airtel, Lupin, L&T, Ashok Leyland, Powergrid, Jyothi Labs, NIIT among others are the top stocks to watch out for in Friday's trading session


BusinessToday.In
June 4, 2020
A Gilead spokesperson told the daily that the manufacturers have been given the authority to set their own prices for the drug


PAGES 1 OF 11  12345